FibroBiologics closed a $3.0 million private placement, issuing pre-funded warrants for up to 4,081,633 shares and short-term and long-term warrants totaling 8,163,266 shares at a $0.735 exercise price, subject to stockholder approval. Net proceeds were about $2.6 million, intended for working capital and general corporate purposes. The company also granted the placement agent fees and warrants, and entered a Registration Rights Agreement committing to file a resale registration statement within 15 days and to maintain effectiveness until the securities are freely tradable. The offering closed on June 29, 2026.
Agreement 1: FibroBiologics Raises $3.0 Million in Private Placement; Issues Pre-Funded and Common Warrants
- Agreement type: Securities Purchase Agreement for private placement of equity-linked securities
- Counterparty: Accredited investor
- Signed / Effective: Jun 25 2026 / Jun 29 2026
- Duration / Termination: At will
- Reason: Strengthen liquidity and fund operations
Agreement 2: FibroBiologics Enters Registration Rights Pact for Private Placement Resale
- Agreement type: Registration Rights Agreement for resale of underlying shares
- Counterparty: Accredited investor
- Signed / Effective: Jun 25 2026 / Jun 25 2026
- Duration / Termination: Until shares are freely tradable
- Reason: Provide resale liquidity to investor
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.